07:00 , Sep 15, 2014 |  BC Week In Review  |  Company News

Abzena, UCL deal

Abzena's Antitope Ltd. subsidiary and University College London partnered to humanize an anti- leucine-rich alpha-2-glycoprotein 1 (LRG1) antibody as part of a Medical Research Council (MRC)-funded translational research and product development program at the UCL...
07:00 , Jul 21, 2014 |  BC Week In Review  |  Company News

Synthon, Abzena deal

Abzena’s Antitope Ltd. subsidiary will use its EpiScreen ex vivo human T cell assay to determine the potential immunogenicity of candidate antibodies for Synthon’s preclinical antibody-drug conjugate (ADC) cancer programs. Synthon declined to disclose details,...
23:41 , Jul 7, 2014 |  BC Extra  |  Financial News

Abzena raises L20 million in London IPO

Abzena Ltd. (LSE:ABZA) raised L20 million ($34 million) through the sale of 25 million shares at 80p in an IPO underwritten by Cenkos Securities. The price values the company at L77.9 million ($132.7 million). Abzena's...
07:00 , Jun 23, 2014 |  BioCentury  |  Finance

Abzena's AIM

Abzena Ltd. is following in the footsteps of other revenue-generating U.K. biopharma service companies by seeking a listing on the LSE's AIM market. CEO John Burt told BioCentury the listing will provide the company enough...
00:43 , Jun 17, 2014 |  BC Extra  |  Financial News

Service/technology provider Abzena files for London IPO

Abzena Ltd. (London, U.K.) proposed an IPO on the London Stock Exchange underwritten by Cenkos Securities plc. Abzena comprises two subsidiaries -- PolyTherics Ltd. and Antitope Ltd. PolyTherics offers site-specific conjugation technologies for antibody-drug conjugate...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Company News

Abzena, Baylor Research Institute deal

Abzena's Antitope Ltd. subsidiary will develop a cell line for the institute's preclinical vaccine targeting dendritic cells to treat head and neck and cervical cancer. Antitope will use its Composite CHO technology, which enables the...
07:00 , Jun 2, 2014 |  BC Week In Review  |  Company News

Abzena antibodies, drug delivery news

PolyTherics Ltd. renamed itself as Abzena Ltd. and said Abzena comprises two subsidiaries - PolyTherics and Antitope. The company will move PolyTherics' operations from London to Cambridge, U.K., where Abzena will also establish its headquarters....
08:00 , Dec 16, 2013 |  BC Week In Review  |  Company News

Annexon, PolyTherics deal

Annexon partnered with PolyTherics' Antitope Ltd. subsidiary to generate antibodies to treat neurodegenerative diseases. Annexon will provide antibodies against undisclosed components of the complement system, and Antitope will use its Composite Human Antibody technology to...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Company News

PolyTherics, Tube Pharmaceuticals deal

PolyTherics and Tube partnered to develop antibody-drug conjugates (ADCs) to treat cancer using PolyTherics' ThioBridge conjugation technology and Tube's cytotoxic synthetic tubulin binding agents called cytolysins. The companies will produce reagents to link antibodies to...
07:00 , Aug 5, 2013 |  BC Week In Review  |  Company News

Antitope, ChemomAb deal

The companies partnered to generate humanized mAbs devoid of T cell epitopes to treat inflammatory diseases using Antitope's Composite Human Antibody technology. Antitope said the deal combines its humanization and immunogenicity technologies with ChemomAb's therapeutic...